Ñîîáùåíèå îò
dant85
Ïðîêîìåíòèðóéòå ïîæàëóéñòà ðåçóëüòàòû èììóíîãðàììû.
Íàïîìíþ, ïîäîçðåâàåòüñÿ ñêðûòàÿ èíôåêöèÿ.
Èììóíîãðàììà:
=============
Îáùèå äàííûå:
Ëåéêîöèòû-5,93
Ëèìôîöèòû-1,97(33,20%)
Ìîíîöèòû-10,1%
-----------------------------------------------Ðåçóëüòàò
Êëåòî÷íûé èììóíèòåò---------------% (x10 â 9é ñòåïåíè/ë)
-------------------------------------------------------------------------------
1)Ò-ëèìôîöèòû(CD3+ CD19-)-------------------------63.61 (1.25)
2)Â-ëèìôîöèòû(CD3- CD19+)-------------------------16.50 (0.33)
3)NÊ-êëåòêè(CD3- CD16+)------------------------------12.90 (0.25)
4)NÊT-êëåòêè(CD3+ CD16+)----------------------------4.97 (0.10)
5)T-õåëïïåðû/Ò-èíäóêòîðû(CD3+ CD4+)------------49.30 (0.97)
6)Ò-ñóïðåññîðû/Ò-öèòîòîêñè÷åñêèå(CD3+ CD8+)--25.20 (0.50)
7)Ò-ëèìôîöèòû íåçðåëûå(CD4+ CD8+)---------------0.72 (0.01)
8)T-õåëïïåðû àêòèâèðîâàíûå(CD25+ CD4+)--------6.51 (0.13)
9)Ò-ëèìôîöèòû àêòèâèðîâàíûå(CD3+ DR+)---------10.5 (0.21)
10)Â-ëèìôîöèòû àêòèâèðîâàíûå(CD3- DR+)--------17.36 (0.34)
11)Èíäåêñ T-õåëïïåðû/Ò-ñóïðåññîðû-----------------------1.96
---------------------------------------------------------------------------------
Ãóìîðàëüíûé èììóíèòåò---------Ðåçóëüòàòû
Èììóíîãëîáóëèíû----------------------Ã/ë
---------------------------------------------------------------------------------
IgA-----------------------------------------------0,87
IgG-----------------------------------------------8,22
IgM-----------------------------------------------0,92
Êîìïîíåíòû êîìïëåìåíòà
----------------------------------------------------------------------------------
Ñ3------------------------------------------------2,60
Ñ4------------------------------------------------0,41
Öèðêóëèðóþùèå èììóííûå êîìïëåêñû-Ìêã/ìë
----------------------------------------------------------------------------------
ÖÈÊ C3d-------------------------------------------18,40
ÖÈÊ C1q-------------------------------------------66,22
Ôàãîöèòàðíàÿ àêòèâíîñòü ãðàíóëîöèòîâ-----81%
Ôàãîöèòàðíàÿ àêòèâíîñòü ìîíîöèòîâ---------59%
Çàêëþ÷åíèå.
----------------------------------------------------------------------------------
Ïîïóëÿöèîííûé ñîñòàâ ëåéêîöèòîâ- ïîâûøåíî îòíîñèòåëüíîå ñîäåðæàíèå
ìîíîöèòîâ.
Ñóáïîïóëÿöèîííûé ñîñòàâ ëèìôîöèòîâ:
 Ò-êëåòî÷íîì çâåíå-íîðìàëüíîå ñîäåðæàíèå Ò-ëèìôîöèòîâ. Ñîîòíîøåíèå
èììóíîðåãóëÿòîðíûõ ñóáïîïóëÿöèé T-õåëïïåðû/Ò-ñóïðåññîðû íå íàðóøåíî.
 Â-êëåòî÷íîì çâåíå - íåçíà÷èòåëüíî ïîâûøåíî îòíîñèòåëüíîå ñîäåðæàíèå
Â-ëèìôîöèòîâ, ñíèæåíà ïðîäóêöèÿ IgA. Ñíèæåíà ôàãîöèòàðíàÿ àêòèâíîñòü
ëåéêîöèòîâ ïðè ïîâûøåííîì ñîäåðæàíèè â ñûðîâîòêå êîìïîíåíòîâ Ñ3 è Ñ4.
Ïîâûøåíà êîíöåíòðàöèÿ ÖÈÊ.
Èçìåíåíèÿ â èììóíîãðàììå ìîãóò ñîîòâåòñòâîâàòü õðîíè÷åñêîìó âîñïàëè-
òåëüíîìó ïðîöåñó, ïðîòåêàþùåìó íà ôîíå ñíèæåííîé ôóíêöèîíàëüíîé
àêòèâíîñòè èììóííîé ñèñòåìû.
Âûðàæåíû èììóíîëîãè÷åñêèå ïðèçíàêè èíòîêñèêàöèè.
---------------------------------------------------------------------